[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1985

Stanozolol in the Treatment of Pityriasis Rubra Pilaris

Author Affiliations

Department of Dermatology Dartmouth-Hitchcock Medical Center Hanover, NH 03755

Arch Dermatol. 1985;121(9):1105-1106. doi:10.1001/archderm.1985.01660090019004
Abstract

To the Editor.—  In response to the short report by Pavlidakey et al1 in the Archives, we, too, were intrigued by the proposal of Finzi et al2 that the underlying defect in pityriasis rubra pilaris (PRP) might be a deficiency of retinol binding protein, resulting in inadequate transport of vitamin A to the skin. Their success in treating three patients with stanozolol,3 an anabolic steroid used to elevate the levels of retinol binding protein, was also of great interest. Our experience in using stanozolol in the treatment of PRP, however, has been less encouraging.In an attempt to duplicate the results of Finzi et al, we gathered a series of five patients with classic adult PRP, diagnosed on clinical grounds with supportive histopathology. As in the case reported by Pavlidakey et al, baseline retinol binding protein levels were within the normal range. Nevertheless, we proceeded with a

First Page Preview View Large
First page PDF preview
First page PDF preview
×